View source for Medicine:Dermatofibrosarcoma protuberans

{{Infobox medical condition (new)
| name       = Dermatofibrosarcoma protuberans
| synonyms        = DFSP
<ref>{{cite web |title=Dermatofibrosarcoma Protuberans Synonyms & Antonyms |url=https://www.synonyms.com/synonym/dermatofibrosarcoma%20protuberans |website=Synonyms.com }}</ref>     
| image           = Dermatofibrosarcoma protuberans (1) recurrence.JPG
| caption         = Histopathological image of dermatofibrosarcoma protuberans. Local recurrence long after the first excision. H&E stain
| pronounce       = 
| field           = 
| symptoms        = 
| complications   = 
| onset           = 
| duration        = 
| types           = 
| causes          = 
| risks           = 
| diagnosis       = 
| differential    = 
| prevention      = 
| treatment       = 
| medication      = 
| prognosis       = 
| frequency       = 
| deaths          = 
}}
'''Dermatofibrosarcoma protuberans''' ('''DFSP''')<ref name="NCI Dictionary of Cancer Terms">{{Cite web|date=2011-02-02|title=NCI Dictionary of Cancer Terms|url=https://www.cancer.gov/publications/dictionaries/cancer-terms|access-date=2020-06-09|website=National Cancer Institute|language=en}}</ref> is a rare locally aggressive malignant cutaneous soft-tissue sarcoma. DFSP develops in the connective tissue cells in the middle layer of the skin (dermis).<ref>{{Cite web|title=Dermatofibrosarcoma protuberans - Overview - Mayo Clinic|url=https://www.mayoclinic.org/diseases-conditions/dermatofibrosarcoma-protuberans/cdc-20352949|access-date=2020-06-09|website=www.mayoclinic.org}}</ref> Estimates of the overall occurrence of DFSP in the United States are 0.8 to 4.5 cases per million persons per year.<ref>{{Cite journal|last1=Rouhani|first1=Panta|last2=Fletcher|first2=Christopher D. M.|last3=Devesa|first3=Susan S.|last4=Toro|first4=Jorge R.|date=2008-08-01|title=Cutaneous soft tissue sarcoma incidence patterns in the U.S. : an analysis of 12,114 cases|journal=Cancer|volume=113|issue=3|pages=616–627|doi=10.1002/cncr.23571|issn=0008-543X|pmid=18618615|s2cid=23746544|doi-access=free}}</ref><ref name="Kreicher S24–31">{{Cite journal|last1=Kreicher|first1=Kathryn L.|last2=Kurlander|first2=David E.|last3=Gittleman|first3=Haley R.|last4=Barnholtz-Sloan|first4=Jill S.|last5=Bordeaux|first5=Jeremy S.|s2cid=12966671|date=January 2016|title=Incidence and Survival of Primary Dermatofibrosarcoma Protuberans in the United States|journal=Dermatologic Surgery|volume=42|issue=Suppl 1 |pages=S24–31|doi=10.1097/DSS.0000000000000300|issn=1524-4725|pmid=26730971}}</ref>  In the United States, DFSP accounts for between 1 and 6 percent of all soft-tissue sarcomas<ref>{{Cite journal|last=Kransdorf|first=M. J.|date=January 1995|title=Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location|journal=American Journal of Roentgenology|volume=164|issue=1|pages=129–134|doi=10.2214/ajr.164.1.7998525|issn=0361-803X|pmid=7998525}}</ref> and 18 percent of all cutaneous soft-tissue sarcomas. In the [[Medicine:Surveillance, Epidemiology, and End Results|Surveillance, Epidemiology and End Results]] (SEER) tumor registry from 1992 through 2004, DFSP was second only to [[Medicine:Kaposi's sarcoma|Kaposi sarcoma]]. 

==Presentation==
Dermatofibrosarcoma protuberans begins as a minor firm area of skin most commonly about  to 1 to 5&nbsp;cm in diameter. It can resemble a bruise, birthmark, or pimple. It is a slow-growing tumor and is usually found on the torso but can occur anywhere on the body.<ref>{{cite web|url=  http://ghr.nlm.nih.gov/condition/dermatofibrosarcoma-protuberans|title= Dermatofibrosarcoma protuberans}}</ref> About 90% of DFSPs are low-grade sarcomas. About 10% are mixed, containing a high-grade sarcomatous component (DFSP-FS); therefore, they are considered to be intermediate-grade sarcomas. DFSPs rarely lead to a [[Medicine:Metastasis|metastasis]] (fewer than 5% metastasize), but DFSPs can recur locally. DFSPs most often arise in patients who are in their thirties but this may be due to diagnostic delay.

=== Location ===
Commonly located on the chest and shoulders, the following is the site distribution of DFPS as was observed in Surveillance, Epidemiology, and End Results (SEER) database between 2000 and 2010.<ref name="Kreicher S24–31"/><ref>{{Cite web |title=America's Children and the Environment: Metadata - Surveillance, Epidemiology, and End Results (SEER) Program |url=https://www.epa.gov/americaschildrenenvironment/metadata-surveillance-epidemiology-and-end-results-seer-program |website=United States Environmental Protection Agency}}</ref>

* Trunk/torso – 42%
* Lower extremity – 21%
* Upper extremity – 21%
* [[Medicine:Head and neck anatomy|Head and neck]] – 13%
* Genitals – 1%

== Variants ==
The [[Organization:World Health Organization|World Health Organization]] in 2020 classified the fibro sarcomatous DFSP (DFSP-FS) variant (also termed dermatofibrosarcoma protuberans, fibro sarcomatous) of the dermatofibrosarcoma protuberans as a specific form of the intermediate (rarely metastasizing) [[Medicine:Fibroblastic and myofibroblastic tumors|fibroblastic and myofibroblastic tumors]] and other variants of this disorder as a specific form of the intermediate (locally aggressive) [[Medicine:Fibroblastic and myofibroblastic tumors|fibroblastic and myofibroblastic tumors]].<ref name="pmid33179614">{{cite journal | vauthors = Sbaraglia M, Bellan E, Dei Tos AP | title = The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives | journal = Pathologica | volume = 113 | issue = 2 | pages = 70–84 | date = April 2021 | pmid = 33179614 | pmc = 8167394 | doi = 10.32074/1591-951X-213 | url = }}</ref>
   
=== Bednar tumors ===
Bednar, or pigmented DFSP, is distinguished by the dispersal of [[Chemistry:Melanin|melanin]]-rich [[Biology:Dendritic cell|dendritic]] cells of the skin. It represents 1–5 percent<ref>{{Cite journal|last1=Liszewski|first1=Walter|last2=Blanchette|first2=Derek|last3=Cunningham|first3=Ashley M.|last4=Miller|first4=Daniel D.|date=2016-11-01|title=Epidemiology of Bednar tumors in the United States|url=https://www.jaad.org/article/S0190-9622(16)30396-6/abstract|journal=Journal of the American Academy of Dermatology|language=English|volume=75|issue=5|pages=1064–1066|doi=10.1016/j.jaad.2016.06.018|issn=0190-9622|pmid=27745635|doi-access=free}}</ref> of all DFSP occurring in people rich in melanin pigments. Bednar is characterized by a dermal spindle cell proliferation like DFSP but distinguished by the additional presence of melanocytic [[Biology:Dendritic cell|dendritic]] cells. It occurs at the same rate as DFSP on fairer skin and should be considered to have the same chances of metastasis.<ref>{{Cite journal|last1=Kaul|first1=Rashmi|last2=Kaur|first2=Navjot|last3=Dogra|first3=Sunder S|last4=Chander|first4=Bal|date=2015|title=Variant of Dermatofibrosarcoma Protuberans: Bednar Tumor|journal=Indian Journal of Dermatology|volume=60|issue=1|pages=107|doi=10.4103/0019-5154.147885|issn=0019-5154|pmc=4318047|pmid=25657441 |doi-access=free }}</ref>

=== Myxoid DFSP ===
Myxoid DFSP has areas of myxoid degeneration in the [[Biology:Stromal cell|stroma]].<ref>{{Cite journal|last1=Reimann|first1=Julie D. R.|last2=Fletcher|first2=Christopher D. M.|s2cid=1268848|date=September 2007|title=Myxoid dermatofibrosarcoma protuberans: a rare variant analyzed in a series of 23 cases|journal=The American Journal of Surgical Pathology|volume=31|issue=9|pages=1371–1377|doi=10.1097/PAS.0b013e31802ff7e7|issn=0147-5185|pmid=17721193}}</ref><ref name=":0">{{Cite web|date=2017-10-24|title=Rare Variants of Dermatofibrosarcoma Protuberans (DFSP)|url=https://www.news-medical.net/health/Rare-Variants-of-Dermatofibrosarcoma-Protuberans-(DFSP).aspx|access-date=2020-06-09|website=News-Medical.net|language=en}}</ref>

=== Giant cell fibroblastoma ===
Giant cell fibroblastoma<ref name="NCI Dictionary of Cancer Terms"/> contains [[Biology:Giant cell|giant cells]], and is also known as juvenile DFSP.<ref>{{Cite journal|last1=Buteau|first1=Anna H.|last2=Keeling|first2=Brett H.|last3=Diaz|first3=Lucia Z.|last4=Larralade|first4=Margarita|last5=Luna|first5=Paula|last6=Krishnan|first6=Chandra|last7=Levy|first7=Moise L.|date=2018-01-16|title=Dermatofibrosarcoma protuberans in pediatric patients: A diagnostic and management challenge|journal=JAAD Case Reports|volume=4|issue=2|pages=155–158|doi=10.1016/j.jdcr.2017.09.022|issn=2352-5126|pmc=5789519|pmid=29387771}}</ref> Giant cell fibroblastomas are skin and soft-tissue tumors that usually arise in childhood. They are sometimes seen in association with dermatofibrosarcoma protuberans (DFSP, hybrid lesions) or may transform or recur as DFSP.<ref>{{Cite web|title=Giant cell fibroblastoma pathology {{!}} DermNet NZ|url=https://dermnetnz.org/topics/giant-cell-fibroblastoma-pathology/|access-date=2020-06-09|website=dermnetnz.org}}</ref><ref name=":0" />

=== Atrophic DFSP ===
Atrophic DFSP resemble other benign lesions such as [[Medicine:Morphea|morphea]], idiopathic atrophoderma, atrophic scar, anetoderma or lipoatrophy. It behaves like classic DFSP. It commonly favours young to middle-aged adults. It has a slow infiltrative growth and a high rate of local recurrence if not completely excised.<ref name=":0" /><ref>{{Cite journal|last1=Bakry|first1=Ola|last2=Attia|first2=Abdalla|date=2012-03-27|title=Atrophic dermatofibrosarcoma protuberans|journal=Journal of Dermatological Case Reports|volume=6|issue=1|pages=14–17|doi=10.3315/jdcr.2012.1089|issn=1898-7249|pmc=3322104|pmid=22514584}}</ref>

=== Sclerosing DFSP ===
Sclerosing DFSP is a variant in which the cellularity is low, and the tumor consists of uniform bundles of collagen interspersed with more typical DFSP cells.<ref name=":0" />

Granular cell variant is a rare type in which spindle cells are mingled with richly granular cells, the granules being lysosomal, with prominent nucleoli.<ref name=":0" />

=== Fibrosarcomatous DFSP (DFSP-FS) ===
Fibrosarcomatous DFSP is a rare variant of DFSP involving greater aggression, high rates of local occurrences, and higher metastatic potential.<ref>{{Cite journal|last1=Abbott|first1=Jared J.|last2=Oliveira|first2=Andre M.|last3=Nascimento|first3=Antonio G.|s2cid=23911032|date=April 2006|title=The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans|journal=The American Journal of Surgical Pathology|volume=30|issue=4|pages=436–443|doi=10.1097/00000478-200604000-00002|issn=0147-5185|pmid=16625088}}</ref>  DFSP-FS are considered to be intermediate-grade sarcomas,<ref>{{Cite journal|last1=Bowne|first1=W. B.|last2=Antonescu|first2=C. R.|last3=Leung|first3=D. H.|last4=Katz|first4=S. C.|last5=Hawkins|first5=W. G.|last6=Woodruff|first6=J. M.|last7=Brennan|first7=M. F.|last8=Lewis|first8=J. J.|date=2000-06-15|title=Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution|journal=Cancer|volume=88|issue=12|pages=2711–2720|doi=10.1002/1097-0142(20000615)88:12<2711::AID-CNCR9>3.0.CO;2-M|issn=0008-543X|pmid=10870053|doi-access=free}}</ref> although they rarely metastasize (fewer than 5 percent of cases).

==Pathophysiology==
More than 90% of DFSP tumors have the [[Biology:Chromosomal translocation|chromosomal translocation]] t(17;22). The translocation fuses the [[Biology:Collagen|collagen]] [[Biology:Gene|gene]] (COL1A1) with the platelet-derived growth factor (PDGF) gene. The fibroblast, the [[Biology:Cell|cell]] of origin of this tumor, expresses the [[Biology:Fusion gene|fusion gene]] in the belief that it codes for collagen. However, the resulting fusion protein is processed into a mature platelet-derived growth factor which is a potent [[Biology:Growth factor|growth factor]]. Fibroblasts contain the [[Biology:Receptor (biochemistry)|receptor]] for this growth factor. Thus the cell "thinks" it is producing a structural [[Biology:Protein|protein]], but it creates a self-stimulatory growth signal. The [[Biology:Cell division|cell divides]] rapidly and tumor forms.

The tissue is often positive for [[Biology:CD34|CD34]].<ref name="pmid12661001">{{cite journal |vauthors=Sirvent N, Maire G, Pedeutour F |title=Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment |journal=Genes Chromosomes Cancer |volume=37 |issue=1 |pages=1–19 |date=May 2003 |pmid=12661001 |doi=10.1002/gcc.10202|s2cid=36985697 }}</ref><ref name="pmid17950782">{{cite journal  |vauthors=Patel KU, Szabo SS, Hernandez VS, etal |title=Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays |journal=Hum. Pathol. |volume=39 |issue=2 |pages=184–93 |date=February 2008 |pmid=17950782 |doi=10.1016/j.humpath.2007.06.009 }}</ref>

==Diagnosis==
[[File:Histopathology of cartwheel pattern in dermatofibrosarcoma protuberans, annotated.jpg|thumb|The pattern of tumor cells radiating from a center is described as "[[Medicine:Cartwheel pattern|cartwheel pattern]]".]]
DFSP is a malignant tumor diagnosed with a [[Medicine:Biopsy|biopsy]], when a portion of the tumor is removed for examination. In order to ensure that enough tissue is removed to make an accurate diagnosis, the initial biopsy of a suspected DFSP is usually done with a core needle or a surgical incision.<ref>{{cite web|url= http://sarcomahelp.org/dermatofibrosarcoma-protuberans.html|title= What is Dermatofibrosarcoma Protuberans?}}</ref>

Clinical palpation is not entirely reliable for ascertaining the depth of a DFSP infiltration. [[Physics:Magnetic resonance imaging|Magnetic resonance imaging]] (MRI) is more sensitive addressing the depth of the invasion on some types of DFSP, particularly large or recurring tumors,<ref>{{Cite journal|last1=Serra-Guillén|first1=Carlos|last2=Sanmartín|first2=Onofre|last3=Llombart|first3=Beatriz|last4=Nagore|first4=Eduardo|last5=Deltoro|first5=Carlos|last6=Martín|first6=Isabel|last7=Borella-Estrada|first7=Rafael|last8=Requena|first8=Celia|last9=Martorell-Calatayud|first9=Antonio|last10=Cervera|first10=Jose|last11=Guillén|first11=Carlos|s2cid=23878054|date=November 2011|title=Correlation between preoperative magnetic resonance imaging and surgical margins with modified Mohs for dermatofibrosarcoma protuberans|journal=Dermatologic Surgery|volume=37|issue=11|pages=1638–1645|doi=10.1111/j.1524-4725.2011.02077.x|issn=1524-4725|pmid=21679274}}</ref><ref>{{Cite journal|last1=Kransdorf|first1=M. J.|last2=Meis-Kindblom|first2=J. M.|date=August 1994|title=Dermatofibrosarcoma protuberans: radiologic appearance|journal=American Journal of Roentgenology|volume=163|issue=2|pages=391–394|doi=10.2214/ajr.163.2.8037038|issn=0361-803X|pmid=8037038}}</ref> though MRI is less accurate for identifying infiltration to head and neck tumors.

== Diagnostic delay and misdiagnosis ==
Due to the rarity, initial presentation of flat plaque (skin hardening) and the slow-growing nature of DFSP, it may be months to years without a protuberance (bump). The dissonance between the name of the neoplasm and its clinical presentations may cause a majority of patients to experience a diagnostic delay. A 2019 research study found out of 214 patients a range between less than a year to 42 years before diagnosis (median, four years) from patients noticing a symptom to diagnosis.<ref name=":2">{{Cite journal|last1=David|first1=Marjorie Parker|last2=Funderburg|first2=Ashley|last3=Selig|first3=James P.|last4=Brown|first4=Rebecca|last5=Caliskan|first5=Pip M.|last6=Cove|first6=Lee|last7=Dicker|first7=Gayle|last8=Hoffman|first8=Lori|last9=Horne|first9=Tammi|last10=Gardner|first10=Jerad M.|date=2019-08-30|title=Perspectives of Patients With Dermatofibrosarcoma Protuberans on Diagnostic Delays, Surgical Outcomes, and Nonprotuberance|journal=JAMA Network Open|volume=2|issue=8|pages=e1910413|doi=10.1001/jamanetworkopen.2019.10413|issn=2574-3805|pmc=6724159|pmid=31469398}}</ref>

Currently, a majority of patients (53%) receive a misdiagnosis by health care providers. The most frequent prebiopsy clinical suspicion included cyst (101 [47.2%]), lipoma (30 [14.0%]), and scar (17 [7.9%]).<ref name=":2" />

It has been suggested an alternative term for DFSP should be ''dermatofibrosarcoma, often protuberant.''<ref name=":2" />

== Pregnancy ==
It is suggested that DFSPs may enlarge more rapidly during pregnancy. Immunohistochemical stains for CD34, S-100 protein, factor XIIIa, and estrogen and progesterone receptors were performed on biopsy specimens. The tumors showed the expression of the progesterone receptor. As with many other stromal neoplasms, DFSPs appear to express low levels of hormone receptors, which may be one factor that accounts for their accelerated growth during pregnancy.<ref>{{Cite journal|last1=Parlette|first1=L. E.|last2=Smith|first2=C. K.|last3=Germain|first3=L. M.|last4=Rolfe|first4=C. A.|last5=Skelton|first5=H.|date=November 1999|title=Accelerated growth of dermatofibrosarcoma protuberans during pregnancy|journal=Journal of the American Academy of Dermatology|volume=41|issue=5 Pt 1|pages=778–783|doi=10.1016/s0190-9622(99)70023-x|issn=0190-9622|pmid=10534646}}</ref>

==Treatment==
[[File:Dermatofibrosarcoma protuberans CT cor.jpg|thumb|Dermatofibrosarcoma protuberans of the left axilla. CT, coronal reconstruction]]
Treatment is primarily surgical, with [[Medicine:Chemotherapy|chemotherapy]] and [[Physics:Radiation therapy|radiation therapy]] used if clear [[Medicine:Resection margin|resection margin]]s are not acquired.<ref name="pmid31466588">{{cite journal | vauthors = Allen A, Ahn C, Sangüeza OP | title = Dermatofibrosarcoma Protuberans | journal = Dermatol Clin | volume = 37 | issue = 4 | pages = 483–488 | date = October 2019 | pmid = 31466588 | doi = 10.1016/j.det.2019.05.006 | s2cid = 201672710 }}</ref>

=== Surgical treatment ===
The type of surgical treatment chosen is dependent on the location of the DFSP occurrence and possible size.

==== Mohs surgery ====
Mohs micrographic surgery (MMS) has a high cure rate and lowers the recurrence reduction of DFSP<ref>{{Cite journal|last1=Malan|first1=Malumani|last2=Xuejingzi|first2=Wu|last3=Quan|first3=Song Ji|date=2019-08-13|title=The efficacy of Mohs micrographic surgery over the traditional wide local excision surgery in the cure of dermatofibrosarcoma protuberans|journal=The Pan African Medical Journal|volume=33|page=297|doi=10.11604/pamj.2019.33.297.17692|issn=1937-8688|pmc=6815477|pmid=31692830}}</ref> if negative resection margins are achieved.

==== Wide local excision ====
[[Medicine:Wide local excision|Wide local excision]] (WLE) was the gold standard for treating DFSP but is currently under reevaluation. Presently in the United States, WLE may be suggested after the recurrence of MMS. Larger resection margins are suggested for WLE than MMS. Recurrence rate with WLE is about 8.5% with a lower recurrence rate related to wider excision.<ref>{{Cite journal|last1=Kim|first1=Byung Jun|last2=Kim|first2=Hyeonwoo|last3=Jin|first3=Ung Sik|last4=Minn|first4=Kyung Won|last5=Chang|first5=Hak|date=2015|title=Wide Local Excision for Dermatofibrosarcoma Protuberans: A Single-Center Series of 90 Patients|journal=BioMed Research International|volume=2015|page=642549|doi=10.1155/2015/642549|issn=2314-6133|pmc=4673335|pmid=26688814|doi-access=free}}</ref>

=== Resection margin ===
DFSP characteristic features are its capacity to invade surrounding tissues, to a considerable distance from the central focus of the tumor in a "tentacle-like" fashion. This fact, coupled with diagnostic delay, may lead to inadequate initial resection. Inadequate initial treatment results in larger, deeper recurrent lesions, but these can be managed by appropriate wide excision.<ref>{{Cite journal|last1=Khatri|first1=Vijay P.|last2=Galante|first2=Joseph M.|last3=Bold|first3=Richard J.|last4=Schneider|first4=Philip D.|last5=Ramsamooj|first5=Rajendra|last6=Goodnight|first6=James E.|date=November 2003|title=Dermatofibrosarcoma protuberans: reappraisal of wide local excision and impact of inadequate initial treatment|journal=Annals of Surgical Oncology|volume=10|issue=9|pages=1118–1122|doi=10.1245/aso.2003.03.581|issn=1068-9265|pmid=14597453|s2cid=41310745}}</ref>

=== Radiation therapy  ===
DFSP is a radioresponsive tumor; radiation therapy (RT) is not used as the first choice for treatment. Conservative resection through MMS or WLE is attempted first. If clear margins are not achieved RT, or chemotherapy is recommended.<ref>{{Cite journal|last1=Suit|first1=H.|last2=Spiro|first2=I.|last3=Mankin|first3=H. J.|last4=Efird|first4=J.|last5=Rosenberg|first5=A. E.|date=August 1996|title=Radiation in management of patients with dermatofibrosarcoma protuberans|journal=Journal of Clinical Oncology|volume=14|issue=8|pages=2365–2369|doi=10.1200/JCO.1996.14.8.2365|issn=0732-183X|pmid=8708729}}</ref>

=== Chemotherapy ===
DFSP was previously regarded and nonresponsive to standard chemotherapy.<ref>{{Cite journal|last1=Noujaim|first1=Jonathan|last2=Thway|first2=Khin|last3=Fisher|first3=Cyril|last4=Jones|first4=Robin L.|date=December 2015|title=Dermatofibrosarcoma protuberans: from translocation to targeted therapy|journal=Cancer Biology & Medicine|volume=12|issue=4|pages=375–384|doi=10.7497/j.issn.2095-3941.2015.0067|issn=2095-3941|pmc=4706526|pmid=26779374}}</ref> In 2006 the US FDA approved (imatinib mesylate) for the treatment of DFSP.<ref>{{Cite journal|date=2006-11-01|title=Gleevec Gains Simultaneous FDA Approval for Five Rare, Life-Threatening Disorders|url=https://www.cancernetwork.com/gastrointestinal-cancer/gleevec-gains-simultaneous-fda-approval-five-rare-life-threatening-disorders|access-date=2020-06-10|website=Cancer Network|series=Oncology NEWS International Vol 15 No 11|volume=15|issue=11|language=en|archive-date=2020-06-10|archive-url=https://web.archive.org/web/20200610130239/https://www.cancernetwork.com/gastrointestinal-cancer/gleevec-gains-simultaneous-fda-approval-five-rare-life-threatening-disorders|url-status=dead}}</ref> As is true for all medicinal drugs with name ending in "ib," imatinib is a small molecular pathway inhibitor; imatinib inhibits [[Biology:Tyrosine kinase|tyrosine kinase]]. It may be able to induce tumor regression in patients with recurrent DFSP, unresectable DFSP, or metastatic DFSP.<ref>{{cite journal |last1=Rastogi |first1=Sameer |last2=Dhamija |first2=Ekta |last3=Barwad |first3=Adarsh |last4=Aggarwal |first4=Aditi |last5=Sharma |first5=Atul |last6=Panday |first6=Rambha |title=Advanced Dermatofibrosarcoma Protuberans Treatment With Imatinib: Experience From a Dedicated Sarcoma Medical Oncology Clinic in India |journal=Journal of Global Oncology |volume=4 |date=December 2018 |issue=4 |pages=1–7 |doi=10.1200/JGO.18.00007 |pmid=30085879 |pmc=6223511 }}</ref> There is clinical evidence that [[Chemistry:Imatinib|imatinib]], which inhibits PDGF-receptors, may be effective for tumors positive for the t(17;22) translocation. It is suggested that imatinib may be a treatment for challenging, locally advanced disease and in the rare metastatic cases. It was approved for use by adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).<ref>{{Cite web|title=Lupin in alliance with Natco receives FDA approval for Imatinib Mesylate Tablets|url=https://www.lupin.com/portfolio/lupin-in-alliance-with-natco-receives-fda-approval-for-imatinib-mesylate-tablets/|access-date=2020-06-10|website=Lupin|date=5 March 2019|language=en-US}}</ref>

== Metastatic disease ==
Distant hematogenous metastases are extremely rare.<ref>{{Cite journal |last1=Mavili |first1=M. E. |last2=Gursu |first2=K. G. |last3=Gokoz |first3=A. |date=April 1994 |title=Dermatofibrosarcoma with lymph node involvement |journal=Annals of Plastic Surgery |volume=32 |issue=4 |pages=438–440 |doi=10.1097/00000637-199404000-00022 |issn=0148-7043 |pmid=8210168}}</ref>  [[Medicine:Metastasis|Metastases]] to regional lymph nodes are rarer and are most likely in patients who have had multiple local recurrences after inadequate surgical resection.<ref>{{Cite journal|last1=Rutgers|first1=E. J.|last2=Kroon|first2=B. B.|last3=Albus-Lutter|first3=C. E.|last4=Gortzak|first4=E.|date=June 1992|title=Dermatofibrosarcoma protuberans: treatment and prognosis|journal=European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|volume=18|issue=3|pages=241–248|issn=0748-7983|pmid=1607035}}</ref> Repeatedly recurring tumors have an increased risk for transformation into a more malignant form (DFSP-FS). The lungs are most frequently affected, but metastases to the brain,<ref>{{Cite journal|last1=Mahajan|first1=B. B.|last2=Sumir|first2=Kumar|last3=Singla|first3=Monika|date=July 2015|title=Metastatic dermatofibrosarcoma protuberans: A rare case report from North India|journal=Journal of Cancer Research and Therapeutics|volume=11|issue=3|pages=670|doi=10.4103/0973-1482.146099|issn=1998-4138|pmid=26458720|doi-access=free}}</ref> bone,<ref>{{Cite journal|last1=Garg|first1=Mandeep Kumar|last2=Yadav|first2=Mukesh Kumar|last3=Gupta|first3=Suruchi|last4=Kumar|first4=Narender|last5=Khandelwal|first5=Niranjan|date=2009-09-29|title=Dermatofibrosarcoma protuberans with contiguous infiltration of the underlying bone|journal=Cancer Imaging|volume=9|issue=1|pages=63–66|doi=10.1102/1470-7330.2009.0011|doi-broken-date=1 August 2023|issn=1740-5025|pmc=2792083|pmid=19933019}}</ref> and other soft tissues are reported.

== Studies ==
DFSP is not extensively studied due to its rarity and low mortality. The majority of studies are small size case studies or meta-analysis.

The most extensive research study to date was ''Perspectives of Patients With Dermatofibrosarcoma Protuberans on Diagnostic Delays, Surgical Outcomes, and Nonprotuberance''.<ref name=":2" /> The lead researcher, Jerad Gardner, spoke at a TED Talk in February 2020 on the topic.<ref>{{Cite web |last=Gardner |first=Jerad |date=2020-06-08 |title=Facebook and Rare Cancer Changed My Life |url=https://www.ted.com/talks/jerad_gardner_facebook_and_rare_cancer_changed_my_life |access-date=2023-09-18 |website=TED Conferences}}</ref>

== History ==
R. W. Taylor, in 1890,<ref>{{Cite journal|last1=Shen|first1=Kuang-Hsuan|last2=Leu|first2=Yi-Shing|date=2017-09-01|title=Dermatofibrosarcoma protuberans of the cheek|journal=Journal of Cancer Research and Practice|language=en|volume=4|issue=3|pages=119–121|doi=10.1016/j.jcrpr.2017.03.001|issn=2311-3006|doi-access=free}}</ref> first identified DFSP as a [[Medicine:Keloid|keloid]] sarcoma. Later in 1924, Ferdinand-Jean Darier and Ferrand identified it as a progressive recurrent dermatofibroma. In 1925, E. Hoffmann<ref>{{Cite journal|last=Hoffmann|first=Erich|date=1925|title=I. Über das knollentreibende Fibrosarkom der Haut (Dermatofibrosarkoma protuberans)|url=https://www.karger.com/Article/FullText/250699|journal=Dermatology|language=english|volume=43|issue=1–2|pages=1–28|doi=10.1159/000250699|issn=1018-8665}}</ref> coined the term ''dermatofibrosarcoma protuberans''. Bednar tumor was first described by Bednar in 1957.<ref>{{Cite web|title=Bednar tumour: an infrequent diagnosis {{!}} British Journal of Medical Practitioners|url=https://www.bjmp.org/content/bednar-tumour-infrequent-diagnosis|access-date=2020-06-09|website=www.bjmp.org}}</ref><ref>{{Cite journal|last=Bednar|first=B.|date=March 1957|title=Storiform neurofibromas of the skin, pigmented and nonpigmented|journal=Cancer|volume=10|issue=2|pages=368–376|doi=10.1002/1097-0142(195703/04)10:2<368::aid-cncr2820100218>3.0.co;2-3|issn=0008-543X|pmid=13426994|s2cid=42490204 |doi-access=free}}</ref>

== ICD coding ==
The following are the [[Medicine:ICD-10|ICD-10]] medical codes:
* ICD-0: 8832/3<ref name=":1">{{Cite web|title=Dermatofibrosarcoma protuberans (DFSP)|url=http://www.pathologyoutlines.com/topic/skintumornonmelanocyticdfsp.html|access-date=2020-06-09|website=www.pathologyoutlines.com}}</ref> – dermatofibrosarcoma protuberans, NOS
* ICD-0: 8833/3<ref name=":1" /> – pigmented dermatofibrosarcoma protuberans
* ICD-0: 8834/1<ref name=":1" /> – giant cell fibroblastoma
* Fibrosarcomatous dermatofibrosarcoma protuberans: no distinct coding identified

==Additional images==
<gallery>
File:SkinTumors-P9280838.JPG|[[Biology:Subcutaneous tissue|Subcutaneous tissue]] infiltration (i.e. "honeycomb" growth pattern)
File:SkinTumors-P9270828.JPG|Monotonous, plexiform structure of tumour
File:SkinTumors-P9280834.JPG|DFSP formed both by fibroblastic and [[Biology:Histiocyte|histiocytic]] elements
File:SkinTumors-P9270830.JPG|[[Medicine:Hemosiderin|Hemosiderin]] deposits beneath the tumour
File:Dermatofibrosarcoma protuberans (5) CD34.JPG|[[Biology:Immunostaining|Immunostain]] positive for [[Biology:CD34|CD34]]
</gallery>

== See also ==
* List of cutaneous conditions

==References==
{{Reflist}}

== External links ==
* [https://rarediseases.info.nih.gov/diseases/9569/dermatofibrosarcoma-protuberans Dermatofibrosarcoma protuberans] in NIH Genetic and Rare Diseases Information Center
{{Medical resources
| DiseasesDB      = 31601
| ICD10           = {{ICD10|C|49||c|49}} (ILDS C49.M24)
| ICD9            = 8832/3
| ICDO            = 8833/3
| OMIM            = 607907
| MedlinePlus     = 
| eMedicineSubj   = derm
| eMedicineTopic  = 97
| MeshID          = D018223
| Orphanet        = 31112
}}

{{Chromosomal abnormalities}}

<!-- retained ancestor category (for non-malignant cases) -->

[[Category:Rare cancers]]

{{Sourceattribution|Dermatofibrosarcoma protuberans}}